Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908380 | 1.00 | TSHR (0.41) | TSHRKMT2ACYP19A1ALDH1A1POLB | |
| SCHEMBL19360123 | 0.84 | TSHR (0.40) | TSHRKMT2ACYP19A1ALDH1A1POLB | |
| SCHEMBL17860025 | 0.83 | TSHR (0.39) | TSHRKMT2ACYP19A1ALDH1A1POLB | |
| SCHEMBL20809974 | 0.79 | TSHR (0.37) | TSHRKMT2ACYP19A1ALDH1A1POLB | |
| SCHEMBL20650777 | 0.78 | — | — | |
| SCHEMBL21557930 | 0.78 | TLR4 (0.33) | TSHRKMT2ACYP19A1MAPK1KDM4E | |
| SCHEMBL19601273 | 0.78 | POLB (0.39) | TSHRKMT2ACYP19A1ALDH1A1POLB | |
| SCHEMBL18522793 | 0.77 | ALDH1A1 (0.33) | ALDH1A1MAPK1MAPTMCOLN3 | |
| SCHEMBL20034793 | 0.77 | KMT2A (0.35) | TSHRKMT2ACYP19A1ALDH1A1POLB | |
| SCHEMBL8375036 | 0.76 | MMP1 (0.33) | TSHRALDH1A1POLBMAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4115909-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2023-01-11 | — | — | EP | disclosed |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2020-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | TSHR 499/4885KMT2A 2876/4885CYP19A1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.